• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ridgetech Unveils 2026 Dual-Engine Growth Strategy to Drive Innovation and Value Creation

    3/4/26 8:30:00 AM ET
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $RDGT alert in real time by email

    HANGZHOU, China, March 4, 2026 /PRNewswire/ -- Ridgetech, Inc. (NASDAQ:RDGT) ("Ridgetech" or the "Company"), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced its dual-engine growth strategy for 2026. The strategy centers on supply chain integration by leveraging its wholesale distribution network, B2B platform, and franchise system. Building on its integrated pharmaceutical and healthcare service platforms, Ridgetech aims to achieve parallel breakthroughs in both business model innovation and value creation, thereby strengthening its long-term growth foundation across China's pharmaceutical and healthcare supply chain.

    Further Strengthening Core Business to Enhance Full-Chain Competitiveness

    Positioning its wholesale business as both a strategic cornerstone and a central hub connecting upstream and downstream resources, Ridgetech is committed to further enhancing its supply chain system. The Company will intensify efforts to strengthen its differentiated advantages in product mix and portfolio by deepening strategic cooperation with core suppliers, reinforcing exclusive agency resources, and expanding its distribution coverage of high-margin domestic and international brands, along with distinctive product lines. The Company believes these initiatives will accelerate its transformation from a traffic-driven to a value-driven business model.

    In parallel, the Company plans to further reinforce its compliance management framework and financial risk control capabilities. Key initiatives include implementing full-process controls for agency products, optimizing rebate settlement mechanisms, and enhancing its direct procurement model for branded products.

    Accelerating Scale and Brand Value Growth Through Digital Innovation

    Within Ridgetech's strategic framework, its wholly owned subsidiary Allright (Hangzhou) Internet Technology Co., Ltd. ("Allright"), an online pharmaceutical and healthcare platform, will continue to function as the core digital engine, empowering B2B business expansion and franchise system development. In 2026, Ridgetech will focus on building a more efficient, intelligent, and collaborative service network. The Company aims to expand Allright's customer base to over 300,000, achieve a 30% year-on-year increase in the number of B2B new customers, and reach an online business penetration rate exceeding 30% in Allright.

    In addition, the Company will continue to expand coverage and strengthen connections with independent pharmacies and clinics in Zhejiang Province, further enhancing Allright's diversified value-added service ecosystem.

    Ridgetech believes that, by leveraging its expertise in Online-to-Offline (O2O) agency operations, medical insurance service integration, and supply chain finance, it can support partners in transitioning from market entry to sustainable growth, thereby enhancing the value and operational efficiency of terminal services. In turn, through this mutually beneficial collaboration, the Allright platform is seeking to fully leverage its strengths in supply chain procurement, advance its exclusive agency systems, and refine pricing mechanisms for key partner brands—ultimately consolidating its market position and pricing power to achieve a dual leap in both scale and brand value.

    Synergistic Dual-Engine Collaboration to Unlock Business Multiplier Effects

    In the strategic landscape, Zhejiang Jiuxin Medicine Co., Ltd. ("Jiuxin Medicine"), Ridgetech's wholly owned offline pharmaceutical wholesale distribution platform, together with Allright, serves as two core growth engines. Each fulfills distinct responsibilities while working collaboratively to drive the in-depth evolution of the pharmaceutical and healthcare ecosystem.

    In 2026, the Company plans to systematically introduce Jiuxin Medicine's supply chain products onto the Allright platform, integrating procurement and sales processes, reducing distribution layers, and improving response speed and operational agility.

    Through deep integration of customer data and procurement demand, the Company believes that it can more precisely support category planning and inventory strategies, achieve efficient coordination between cash flow and product flow, and significantly enhance turnover efficiency.

    At the same time, both engines will jointly conduct recruitment activities, leveraging front-end procurement advantages to improve franchise appeal while using back-end digital tools to strengthen partner confidence. This approach is designed to establish a virtuous cycle in which "procurement drives sales and sales guide procurement." Through continued data sharing and business process reengineering, Ridgetech believes it can further streamline channels from upstream suppliers to end-user pharmacies, building a smart distribution system that accurately matches supply and demand, responds rapidly, and fulfills its mission of "delivering quality medicines to those in need."

    Management Commentary

    Mr. Frank Zhao, Interim Chief Executive Officer and Chief Financial Officer of Ridgetech, commented: "In recent years, as demographic trends, policy orientation, and emerging technologies continue to reshape China's pharmaceutical and healthcare industry, the sector has entered a critical phase of profound transformation and accelerated restructuring. In response to these dynamics, we remain firmly committed to our strategic positioning—strengthening foundations while advancing innovation, combining quality improvement with efficiency enhancement, and pursuing parallel breakthroughs in business models and value creation. We believe this strategy is best suited to guide the Company toward high-quality development and to strengthen its industry position and market influence.

    Looking ahead, Ridgetech will work toward achieving its 2026 and medium- to long-term strategic objectives through a clear strategic roadmap, a more streamlined operating system, and a more open collaborative framework. Amid the sweeping transformation of the industry, we are confident that pragmatic execution will enable us to write a new chapter of development, driven by stronger core business capabilities and service strengths. We remain committed to creating greater value for our shareholders and contributing to the national Healthy China 2030 initiative."

    About Ridgetech, Inc.

    Ridgetech, Inc., formerly known as China Jo-Jo Drugstores, Inc. ("Ridgetech" or the "Company"), is a growing online and offline wholesale distributor of pharmaceutical and other healthcare products in China. Ridgetech actively trades on popular online distribution platforms nationwide and has its own online distribution platform. The Company believes that trading on these platforms offers greater opportunities to distribute pharmaceutical products nationwide. For more information about the Company, please visit www.ridgetch.com. The Company routinely posts important information on its website.

    Forward-Looking Statements

    Certain statements in this press release are forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. These forward-looking statements include, but are not limited to, statements concerning the Company's strategic plans and growth initiatives, including supply chain integration, expansion of branded products, development of its digital platform, integration of its wholesale and online operations, and anticipated operational and growth benefits. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to," or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Factors that could cause actual results or events to differ materially from those reflected in the Company's forward-looking statements including risks related to the Company's ability to satisfy applicable procurement conditions, changes in market demand, the Company's ability to successfully implement and promote its digital platform, and those other risks described in the Company's most recent registration statement, most recent annual report on Form 20-F and in its other filings with the U.S. Securities and Exchange Commission.

    For more information, please contact:

    Company Contact: 

    Frank Zhao

    Interim Chief Executive Officer and Chief Financial Officer

    +86-571-88077108

    [email protected]

    Investor Relations Contact:

    Tina Xiao

    Ascent Investor Relations LLC

    +1-646-932-7242

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/ridgetech-unveils-2026-dual-engine-growth-strategy-to-drive-innovation-and-value-creation-302702817.html

    SOURCE Ridgetech, Inc.

    Get the next $RDGT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RDGT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RDGT
    SEC Filings

    View All

    SEC Form 6-K filed by Ridgetech Inc.

    6-K - Ridgetech Inc. (0001856084) (Filer)

    4/3/26 12:00:02 PM ET
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 6-K filed by Ridgetech Inc.

    6-K - Ridgetech Inc. (0001856084) (Filer)

    3/5/26 4:30:37 PM ET
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 424B5 filed by Ridgetech Inc.

    424B5 - Ridgetech Inc. (0001856084) (Filer)

    12/30/25 8:00:13 AM ET
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $RDGT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ridgetech, Inc. Announces 1-for-150 Reverse Share Split

    HANGZHOU, China, April 3, 2026 /PRNewswire/ -- Ridgetech, Inc., a Cayman Islands exempted company (the "Company") (NASDAQ:RDGT), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced that it expects to implement a 1-for-150 reverse share split on its ordinary shares ("Ordinary Shares") effective Tuesday, April 7, 2026 at 5:00 p.m. Eastern Time, with trading to begin on a split‑adjusted basis at the market open on the next trading day. Trading in the Ordinary Shares will continue on the Nasdaq Capital Market under the symbol "RDGT." The new CUSIP number for the Ordinary Shares following the reverse share split is G2124G 203. As of April 2, 2026, the

    4/3/26 12:00:00 PM ET
    $CJJD
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Ridgetech Unveils 2026 Dual-Engine Growth Strategy to Drive Innovation and Value Creation

    HANGZHOU, China, March 4, 2026 /PRNewswire/ -- Ridgetech, Inc. (NASDAQ:RDGT) ("Ridgetech" or the "Company"), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced its dual-engine growth strategy for 2026. The strategy centers on supply chain integration by leveraging its wholesale distribution network, B2B platform, and franchise system. Building on its integrated pharmaceutical and healthcare service platforms, Ridgetech aims to achieve parallel breakthroughs in both business model innovation and value creation, thereby strengthening its long-term growth foundation across China's pharmaceutical and healthcare supply chain. Further Strengthening Co

    3/4/26 8:30:00 AM ET
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Ridgetech, Inc. Reports Fiscal Year 2025 Financial Results

    HANGZHOU, China, July 28, 2025 /PRNewswire/ -- Ridgetech, Inc. (Nasdaq: RDGT) ("Ridgetech" or the "Company"), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced its financial results for the fiscal year ended March 31, 2025. Mr. Frank Zhao, Interim Chief Executive Officer and Chief Financial Officer of Ridgetech, commented, "We are pleased to present a relatively stable revenue outcome for fiscal year 2025, a year marked by significant transformation for the Company. During this period, we divested our retail pharmacy business and acquired Ridgeline and its subsidiary, Allright (Hangzhou) Internet Technology Co. Ltd ("Allright"), marking our st

    7/28/25 9:00:00 AM ET
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $RDGT
    Financials

    Live finance-specific insights

    View All

    Ridgetech, Inc. Reports Fiscal Year 2025 Financial Results

    HANGZHOU, China, July 28, 2025 /PRNewswire/ -- Ridgetech, Inc. (Nasdaq: RDGT) ("Ridgetech" or the "Company"), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced its financial results for the fiscal year ended March 31, 2025. Mr. Frank Zhao, Interim Chief Executive Officer and Chief Financial Officer of Ridgetech, commented, "We are pleased to present a relatively stable revenue outcome for fiscal year 2025, a year marked by significant transformation for the Company. During this period, we divested our retail pharmacy business and acquired Ridgeline and its subsidiary, Allright (Hangzhou) Internet Technology Co. Ltd ("Allright"), marking our st

    7/28/25 9:00:00 AM ET
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples